Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
2024年7月31日 - 9:50PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the appointment of Jennifer
Fox as Chief Legal Officer, effective September 3, 2024.
Fox brings nearly two decades of legal experience in the life
sciences sector. Her expertise spans intellectual property,
litigation, and regulatory matters, gained through roles in both
in-house and private practice settings at industry-leading
companies. As Chief Legal Officer, Fox’s responsibilities will
encompass a wide range of areas, including support and counsel for
all legal affairs, intellectual property, patent protection,
mergers and acquisitions, litigation, regulatory and quality
assurance, compliance, privacy, and government affairs.
“Jennifer is a seasoned legal leader with a deep understanding
of the biotech industry landscape and a remarkable ability to build
cohesive teams,” said Paul J. Diaz, President and CEO of Myriad
Genetics. “Her industry experience and expertise, combined with her
integrity, practical insight, and operational excellence, will be
essential in guiding our legal strategy. We are immensely fortunate
to welcome such a skilled legal expert to our executive team at
Myriad Genetics.”
Fox most recently served as the Executive Vice President of
External Affairs for Emergent BioSolutions where she was
responsible for overseeing legal functions, government and public
affairs, communications, and ESG initiatives. Prior to that role,
she held positions with Brinks, Gilson & Lione, Novozymes North
America and GSK. Fox holds a J.D. from North Carolina Central
University, an M.S. in Biochemistry and Molecular Biology from the
University of Toledo, and a B.S. in Biology, also from the
University of Toledo.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
Fox will be essential in guiding the company’s legal strategy.
These “forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on February 28, 2024, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Media Contact:Glenn Farrell(385)
318-3718PR@myriad.com
Investor Contact:Matt Scalo(801)
584-3532IR@myriad.com
To view Jennifer Fox: Myriad
Genetics Appoints Jennifer Fox as Chief Legal Officer,
please visit the following
link: https://www.globenewswire.com/NewsRoom/AttachmentNg/89f4e64c-0023-4324-aada-018f70199e3f
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 7 2024 まで 7 2024
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 7 2023 まで 7 2024